This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Global > United States > Services > Financial Advisory Services > Transparency in Life Sciences

Global site selector

Transparency in Life Sciences

Addressing the Physician Payments Sunshine Act

Life sciences organizations face the challenge of converting great discoveries and research breakthroughs into public acceptance and market success. For companies specializing in pharmaceuticals, biotechnology, medical products and technology and medical devices, the life sciences are changing at a remarkable rate. Along with change come new challenges. The Physician Payments Sunshine Act, and other pending regulatory activity in the sector, are bringing a new era of transparency requirements to an evolving industry.

Watch our short video to learn ways life sciences companies are addressing the Sunshine Act and data concerns, new scrutiny for research and development (R&D) and stronger and more complex international enforcement.

The Sunshine Act and transparency

The full transcript of the above video is available, here, for your convenience.

Meet our Deloitte leaders and guests

Jeremy Perisho, partner, Deloitte Financial Advisory Services LLP
Yogesh Bahl, partner, Deloitte Financial Advisory Services LLP
Michael Loucks, partner, Skadden, Arps, Slate, Meagher & Flom LLP

Explore further

Deloitte life sciences health care professional (HCP) aggregate spend
Recent laws and public demands for more transparency have caused additional challenges, even for companies who have already implemented HCP aggregate spend solutions. It is important that companies know both how to be in compliance, and ways to capitalize on the hidden data to drive commercial business decisions.
Moving toward the light - the Sunshine Act
The Sunshine Act will soon require manufacturers to record all “transfers of value” to health care professionals. The act’s transparency requirements present some very challenging and complex operational requirements. But are the challenges insurmountable?
Advanced analytics: Good medicine for life sciences
With a large number of compounds going off patent, life sciences companies have to learn how to do more with less. Data analytics can help focus investments, minimize expenses and stop problems before they start. Tune into this episode of Deloitte Insights to learn more about the role of advanced analytics in the life sciences industry.
Life sciences and health reform
For life sciences companies, the 2010 Patient Protection and Affordable Care Act brings direct impacts. However, indirect impacts related to the changing nature of their relationships to other sectors and the choice and consumption of their products could be an even greater catalyst for transformation. Tune into this episode of Deloitte Insights to learn more about the impact of health care reform on the life sciences industry.